NYSE: GKOSGlaukos Corp Stock
$103.35-3.17 (-2.98%)
Updated May 29, 2026
GKOS Price
$103.35
Fair Value Price
N/A
Market Cap
$6.07B
52 Week Low
$73.16
52 Week High
$148.11
P/E
-31.41x
P/B
9.05x
P/S
11.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$551.35M
Earnings
-$189.33M
Gross Margin
57.6%
Operating Margin
-34.45%
Profit Margin
-34.3%
Debt to Equity
0.33
Operating Cash Flow
-$9M
Beta
1.21
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GKOS Overview
Glaukos Corporation is an ophthalmic technology and pharmaceutical company developing novel therapies to treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, and iStent inject W micro-bypass stents that enhance aqueous humor outflow and are inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Glaukos was incorporated in 1998 and is headquartered in San Clemente, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GKOS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important GKOS news, forecast changes, insider trades & much more!
GKOS News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GKOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GKOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GKOS is poor value based on its book value relative to its share price (9.05x), compared to the US Medical Devices industry average (2.93x)
P/B vs Industry Valuation
GKOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GKOS due diligence checks available for Premium users.
Valuation
GKOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-31.41x
Industry
21.32x
Market
23.22x
GKOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.05x
Industry
2.93x
GKOS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GKOS's financial health
Profit margin
Revenue
$150.6M
Net Income
-$19.8M
Profit Margin
-13.1%
GKOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GKOS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$893.3M
Liabilities
$222.4M
Debt to equity
0.33
GKOS's short-term assets ($485.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GKOS's short-term assets ($485.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GKOS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GKOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
$10.5M
Financing
$15.8M
GKOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GKOS vs Medical Device Stocks
Glaukos Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.